VolitionRx Limited (NYSE: VNRX ) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations.
The multi-national epigenetics firm demonstrated strong momentum across its core diagnostic verticals, including sepsis monitoring, human oncology detection, and companion animal health, positioning the company to address total market opportunities exceeding $26 billion.
Sepsis Validations And Point-Of-Care Progress
In sepsis, Critical Care Medicine published independent, peer-reviewed data confirming that the Nu.Q NETs H3.1 biomarker serves as an independent predictor of 28-day mortality and renal replacement therapy.
This validates the assay’s clinical utility for severe sepsis, which features a $2.8 billion total addressable market . Volition is preparing for the September 2026 recruitment start of France’s $7.3 million government-backed DETECSEPS evaluation.
Read Next Trading IdeasGuardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.
2 min read Read this articleSimultaneously, the company confirmed clinical correlation for its bedside finger-prick lateral flow prototype, potentially broadening testing beyond centralized laboratories .
Cancer Detection Milestones And Reimbursement Strategy
In cancer care, Volition published clinical data demonstrating that its Capture-Seq platform identified over 95% of Stage I and II early cancers with 95% specificity, underpinning an annualized $23 billion early detection opportunity.
TrendingAdditionally, the business actively prepares a conditional reimbursement filing in France for its lung cancer test by the end of 2026 following initial pre-submission meetings .
Veterinary Pipeline Progress And Commercial Partnerships
The company also broadened its veterinary pipeline by submitting a manuscript for its Nu.Q Vet feline lymphoma test. Upon peer-reviewed publication, this study will unlock an anticipated $5 million contractual milestone payment .
To support global distribution, Volition transferred its Nu.Q NETs assay to Sysmex Corporation’s platform and maintains active discussions with more than twelve major liquid biopsy and diagnostic firms .
VNRX Price Action: VolitionRX shares were up 100.47% at $0.68 during premarket trading on Thursday. The stock is trading near its 52-week low of $0.32, according to Benzinga Pro data .
Read Next TechAI Arms Race Fuels More Cyberattacks — and More Spending, CrowdStrike Says
CrowdStrike stock surges premarket after beating Q2 estimates with $1.47B revenue and raising its full-year fiscal forecast. Buy CRWD?
4 min read Read this articleImage Via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News General Penny Stocks Top Stories Health Care Why It's Moving